Research search

Reset all

287 matching records Analyze trends Open JSON Open API Download SQLite

Keyword search Author

Substances Psilocybin 3833 Psilocin 553

Date range quick select Last month Last year Last 5 years All time Custom range

BibTeX RIS CSV JSON SQLite

Executed search Sources: ClinicalTrials.gov 287 matching records are displayed.

Clear search

Latest Publications

Most recently published records currently stored in SQLite.

1-20

Last updated: Jul 3, 2026 00:16 UTC

Checking for newly published papers…

287 matching results

A Double-blind, Randomized Trial Examining the Preliminary Efficacy of Psilocybin Therapy for People With Chronic Low Back Pain

This study evaluates whether psilocybin therapy helps patients cope with chronic low back pain more effectively. Patients may be recruited at Stanford and University of California San Francisco (UCSF), study procedures will occur at UCSF. Each participant will receive a dose of psilocybin with possibly one or more other drugs. Participants will undergo two p...

ClinicalTrials.gov 2026-04-28 Joshua Woolley, MD, PhD

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionChronic PainEmotional Processing Clinical Trial Chronic Low-back PainPsilocybin therapy with Zolpidem and Modafinil

Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder

This is a proof-of-concept randomized clinical trial of psilocybin-enhanced psychotherapy versus treatment-as-usual among individuals being treated for methamphetamine use disorder. The trial will take place with individuals admitted to a residential rehabilitation treatment program. The treatment protocol will consist of 4 preparatory therapy visits, 2 psil...

ClinicalTrials.gov 2026-04-21 Portland VA Research Foundation, Inc

ClinicalTrials.gov CLINICAL TRIAL psilocybin Clinical TrialSafety Clinical Trial Amphetamine-Related DisordersPsilocybin

A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)

One hundred participants, ages 21 to 65, who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for major depressive disorder (MDD) will be stratified by study site and randomized with a 1-to-1 allocation under double-blind conditions to receive a single 25 mg oral dose of psilocybin or a single 100 mg oral dose of niacin. Niacin wil...

ClinicalTrials.gov 2026-04-21 Usona Institute

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionHealthy VolunteersSafety Clinical Trial Depressive DisorderMajor

Toward Patient-Tailored Care for Treatment-Resistant Depression: A Pilot Patient-Preference Clinical Trial of Music and Mindfulness in Psilocybin-Assisted Psychotherapy

The goal of this pilot clinical trial is to learn whether it is feasible to individually tailor psilocybin-assisted psychotherapy (PAP) for people with treatment-resistant depression (TRD) based on their personal preferences. The study also aims to explore whether two different psychotherapy styles, music-centered and mindfulness-centered, influence how peop...

ClinicalTrials.gov 2026-04-21 Kyle Greenway

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionWellbeingClinical TrialTreatment-Resistant DepressionSafety Clinical Trial Treatment-Resistant Major Depressive DisorderPsilocybin 25mg

Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in Remission

The goal of this clinical trial is to test whether psilocybin along with therapy in women with early breast cancer and ovarian cancer in remission can improve their fear of recurrence. The main question\[s\] it aims to answer \[is/are\]: Does psilocybin assisted therapy improve fear of cancer recurrence? Does psilocybin assisted therapy improve anxiety, depr...

ClinicalTrials.gov 2026-04-20 University of Colorado, Denver

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionAnxietyClinical TrialObservational Study Clinical Trial Breast CancerOvarian Cancer

Open Label Psilocybin Brain Stimulation and Imaging Pilot Study

This open-label pilot psilocybin administration study investigates the influence of psilocybin on brain function and cognitive control functions in clinically and psychiatrically healthy volunteers. Participants will undergo experimental drug administration sessions after careful screening and preparation. Participants will also have brain activity measured ...

ClinicalTrials.gov 2026-04-19 Johns Hopkins University

ClinicalTrials.gov CLINICAL TRIAL psilocybin Brain ImagingAgingHealthy Volunteers Other Healthy VolunteersPsilocybin 25 mgs

Probing the Functional Magnetic Resonance Imaging Response to Psilocybin in Functional Neurological Disorder (PsiFUND)

The goal of this study is to learn about the brain network response in people who have functional neurological disorder who are administered with a single dose of the psychedelic psilocybin with therapeutic support. The main question it aims to answer is: Can the default mode network, a brain network thought to be relevent in FND, be modified by the administ...

ClinicalTrials.gov 2026-04-16 King's College London

ClinicalTrials.gov CLINICAL TRIAL psilocybin Brain ImagingDefault Mode NetworkAging Other Functional Neurological DisorderPsilocybin

CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical Trial

The goal of this randomized placebo controlled trial is to compare the antidepressant effect of a single oral dose of psilocybin 25 mg compared to 1 mg in 100 patients with cancer related major depressive disorder. The main question it aims to answer is: The primary objective of this study is to evaluate the efficacy of a single 25 mg oral dose of psilocybin...

ClinicalTrials.gov 2026-04-12 Section for Affective Disorders; Northern Stockholm Psychiatry

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionClinical Trial Clinical Trial MDDpsilocybin 25 mg sod

Safety Profile of 25 mg Psilocybin in Individuals With Cocaine Use Disorder

The purpose of this study is to establish the safe administration of psilocybin in individuals with cocaine use disorder in terms of cardiovascular (e.g., heart rate) and subjective (e.g., mood) effects. The study's subject population consists of men and women between the ages of 21 and 55 from the Los Angeles area that meet criteria for cocaine use disorder...

ClinicalTrials.gov 2026-04-06 University of California, Los Angeles

ClinicalTrials.gov CLINICAL TRIAL psilocybin AddictionBrain ImagingAgingHealthcare WorkersSafety Other Cocaine Use DisorderPsilocybin

Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)

The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing. Researchers will compare different doses of psilocybin combined with midazolam or placebo to see what dose induce...

ClinicalTrials.gov 2026-04-02 University of Wisconsin, Madison

ClinicalTrials.gov CLINICAL TRIAL psilocybin NeuroplasticityBrain ImagingWellbeingEmotional ProcessingClinical Trial Clinical Trial PsilocybinPsilocybine

Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of Psilocybin

This study will examine whether combining a single dose of psilocybin with non-invasive transcutaneous auricular vagus nerve stimulation (taVNS), a potential inducer of neuroplasticity and enhanced memory formation, will enhance the long-term beneficial behavioral effects of psilocybin when compared to sham taVNS or no VNS by allowing memory for insights gai...

ClinicalTrials.gov 2026-04-02 University of Wisconsin, Madison

ClinicalTrials.gov CLINICAL TRIAL psilocybin NeuroplasticityWellbeingClinical TrialSafety Clinical Trial HealthyPsychedelic Experiences

Acute Analgesic Effects of DMT on Experimentally Induced Acute Nociceptive Pain, Hyperalgesia and Allodynia in Healthy Participants

N,N-dimethyltryptamine (DMT) is a classical psychedelic with similar effects like LSD or psilocybin. Preliminary evidence from case series and small open-label trials suggests that psychedelics may be promising candidates for the treatment of several pain-related diseases such as chronic pain, migraine, cluster headache or phantom limb pain. However, data fr...

ClinicalTrials.gov 2026-04-01 University Hospital, Basel, Switzerland

ClinicalTrials.gov CLINICAL TRIAL psilocybin Chronic PainHeadache / MigraineClinical TrialCase ReportHealthy Volunteers Clinical Trial HealthyIntravenous infusion of DMT

Effects of Psilocybin in Obsessive Compulsive Disorder

This study will test the feasibility, safety, and evidence for efficacy of psilocybin administration in participants with obsessive compulsive disorder (OCD). This will serve as a preliminary proof of concept study for future larger studies aimed to investigate the utility, cognitive mechanisms, and neural correlates of this intervention. Participants in thi...

ClinicalTrials.gov 2026-04-01 Johns Hopkins University

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionAnxietyOCDMechanism of ActionSafety Other Obsessive-Compulsive DisorderPsilocybin

Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in Depression

The goal of this neuroimaging clinical trial is to test whether psilocybin produces significant immediate changes in functional brain activity in networks associated with mood regulation and depression compared to placebo in patients with depression. The trial aims to determine if psilocybin: 1. Changes connectivity within brain networks associated with mood...

ClinicalTrials.gov 2026-03-29 Sunnybrook Health Sciences Centre

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionBrain ImagingAgingClinical Trial Clinical Trial Depressive DisorderMajor Depressive Disorder

Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder

The goal of this clinical trial is to learn if a single dose of psilocybin (5mg Vs 10mg Vs 25mg) alongside psychotherapy is safe and can help treat treatment resistant depression (TRD) with co-occurring substance use disorder (SUD) in veterans and first responders. We seek to answer: * Whether 5mgs, 10mgs and 25mgs of psilocybin are safe in individuals with ...

ClinicalTrials.gov 2026-03-29 Indiana University

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionAddictionBrain ImagingDefault Mode NetworkMystical ExperienceClinical TrialTreatment-Resistant DepressionVeteransSafety Clinical Trial Treatment Resistant DepressionSubstance Use Disorders

Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression

This Phase 2a pilot, exploratory, randomized, double-blind, placebo-controlled, parallel-group trial will estimate whether concurrent fluoxetine alters the antidepressant effect, acute psychedelic experience, or safety of a psychedelic-assisted psychotherapy session in adults with treatment-resistant major depressive disorder (TRD). Eligible participants (ag...

ClinicalTrials.gov 2026-03-26 Federal University of Latin American Integration

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionClinical TrialTreatment-Resistant DepressionSafety Clinical Trial Depressive DisorderPsilocybin and Psilocyn

The QUANTUM Trip Trial - Psilocybin-assisted Therapy for Reducing Alcohol Intake in Patients With Alcohol Use Disorder: A Randomized, Double-blinded, Placebo-controlled Clinical Trial.

Note: The trial is only eligible for citizens of Denmark. The purpose of this project is to assess the treatment efficacy of a single high dose of psilocybin administered within a protocol of psychological support to patients diagnosed with alcohol use disorder (AUD). To establish efficacy, we will investigate a single dose of psilocybin versus placebo in a ...

ClinicalTrials.gov 2026-03-23 Anders Fink-Jensen, MD, DMSci

ClinicalTrials.gov CLINICAL TRIAL psilocybinpsilocin AddictionBrain ImagingBiomarkersAgingClinical Trial Clinical Trial Alcohol Use DisorderPsilocybin

Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects: A Randomized, Open-Label, Cross-Over Functional Magnetic Resonance Imaging Trial

The goal of this clinical trial is to systematically categorize potential prohedonic effects of psilocybin in patients with anhedonia in depression. The main questions it aims to answer are: Primary Objectives 1. Systematically categorize prohedonic effects (antianhedonic effects in patients with anhedonia in depression, increase in well-being in all partici...

ClinicalTrials.gov 2026-03-23 Medical University of Vienna

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionNeuroplasticityBrain ImagingReceptor PharmacologyAgingWellbeingClinical TrialInflammation Clinical Trial Depression - Major Depressive DisorderAnhedonia

Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies

PRE-EMPT will assemble a study group of 150 civilian and Veteran participants from three populations (low risk, intermediate risk, and high risk for self-harm). The investigators will obtain clinical assessments, MRI, and blood levels for circular RNA (circRNA). The teams will then administer three interventions (neurofeedback, transcranial magnetic stimulat...

ClinicalTrials.gov 2026-03-19 University of New Mexico

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionPTSDNeuroplasticityBrain ImagingMechanism of ActionBiomarkersAgingEmotional ProcessingObservational StudyVeteransSafetyTranscriptomics Observational Study Suicidal IdeationfMRI Neurofeedback

Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand Mechanism

We propose a first-of-its-kind open-label clinical trial to investigate the feasibility, tolerability, and safety of administering psilocybin in autistic adults with treatment-resistant depression (TRD). In this study, 20 participants (intellectually able and fluent-speech adults) with autism and co-occurring TRD will receive around 20 hours of manualized ps...

ClinicalTrials.gov 2026-03-19 Centre for Addiction and Mental Health

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionConsciousnessClinical TrialTreatment-Resistant DepressionSafety Clinical Trial Treatment Resistant DepressionAutism Spectrum Disorder

Email alerts Open a focused sheet to subscribe broadly or narrow notifications by keyword, author, journal, topic, substance, and cited DOI.

Analytics Open a focused analytics workspace for timeline ranges, publication trends, top journals, topics, and authors.

Source	Count	Share	Status
Europe PMC	2,553	64.2%	Active
PubMed	302	7.6%	Active
ClinicalTrials.gov	287	7.2%	Active
OpenAlex	283	7.1%	Active
PsyArXiv	216	5.4%	Active
Crossref	157	4%	Active
bioRxiv	142	3.6%	Active

Psilocybin Research Publication Tracker

Research search

Latest Publications